Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
Mahali S. Morgan(The University of Queensland), Jody Hobson‐Peters(The University of Queensland), Alexander A. Khromykh(The University of Queensland), Daniel J. Rawle(QIMR Berghofer Medical Research Institute), Alberto A. Amarilla(Commonwealth Scientific and Industrial Research Organisation), James R. Potter(The University of Queensland), Julian D. J. Sng(The University of Queensland), Kexin Yan(QIMR Berghofer Medical Research Institute), Daniel Watterson(The University of Queensland), David A. Muller(Cornell University), Roy A. Hall(The University of Queensland), Ryan Johnston(The University of Queensland), Andreas Suhrbier(The University of Queensland), Devina Paramitha(The University of Queensland), Mary Lor(QIMR Berghofer Medical Research Institute), Naphak Modhiran(The University of Queensland), Christopher L. D. McMillan(The University of Queensland), Thuy T. Le(The University of Melbourne), Ariel Isaacs(The University of Queensland)
Cited by 21
Related Papers
Taxonomy of the order Bunyavirales: update 2019
|Archives of Virology|2019|405
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.
|The Journal of Experimental Medicine|1994|281
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
|Cell|2021|236
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
Emerging Viral Diseases of Southeast Asia and the Western Pacific
|Open MIND|2001|205